For patients whose primary concern is visceral fat reduction specifically, our clinical comparison of Tesamorelin versus Sermorelin, which covers the FDA-approval data behind Tesamorelins fat loss indication and why it outperforms sermorelin for that specific goal, covers that decision in detail
The FDA has warned patients to be cautious with unapproved GLP-1 products and notes that compounded drugs are not reviewed by the agency for safety, effectiveness, or quality before marketing
Retatrutide is studied in research settings as a triple glucagon / GIP / GLP-1 receptor agonist, with interest in multi-incretin signaling, energy-expenditure models, food-intake models, glycemic endpoints, and body-composition research
We invite you to experience the difference for yourself
They use the exact same pure ingredient that is in the big brand-name drugs